While Moderna Inc has underperformed by -0.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRNA fell by -25.08%, with highs and lows ranging from $48.92 to $22.28, whereas the simple moving average jumped by 13.49% in the last 200 days.
On December 12, 2025, Jefferies started tracking Moderna Inc (NASDAQ: MRNA) recommending Hold. A report published by Citigroup on March 13, 2025, Initiated its previous ‘Neutral’ rating for MRNA. Barclays also Downgraded MRNA shares as ‘Equal Weight’, setting a target price of $45 on the company’s shares in a report dated February 18, 2025. Goldman January 29, 2025d the rating to Neutral on January 29, 2025, and set its price target from $99 to $51. Argus December 18, 2024d its ‘Buy’ rating to ‘Hold’ for MRNA, as published in its report on December 18, 2024. BofA Securities’s report from December 10, 2024 suggests a price prediction of $41 for MRNA shares, giving the stock a ‘Underperform’ rating. Berenberg also rated the stock as ‘Hold’.
Analysis of Moderna Inc (MRNA)
Further, the quarter-over-quarter decrease in sales is -45.44%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Moderna Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -29.32% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and MRNA is recording an average volume of 10.70M. On a monthly basis, the volatility of the stock is set at 5.12%, whereas on a weekly basis, it is put at 5.12%, with a loss of -7.84% over the past seven days. Furthermore, long-term investors anticipate a median target price of $35.89, showing growth from the present price of $31.15, which can serve as yet another indication of whether MRNA is worth investing in or should be passed over.
How Do You Analyze Moderna Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.54%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 70.21% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
